BACKGROUND: Allergen-specific immunotherapy is clinically effective for the treatment of cat allergy but shows a high rate of side effects. OBJECTIVE: We sought to engineer recombinant fusion proteins for cat immunotherapy that allow reducing both IgE-mediated and T cell-mediated side effects. METHODS: Fusion proteins consisting of the hepatitis B virus-derived PreS domain and 2 nonallergenic Fel d 1-derived peptides were expressed in Escherichia coli and purified. IgE reactivity and allergenic activity of Fel d 1 and the fusion proteins were compared by using IgE-binding assays and basophil activation tests in patients with cat allergy. Mice and rabbits were immunized subcutaneously with Fel d 1 and the fusion proteins to investigate the allergenicity of the vaccines and the development of Fel d 1-specific IgG antibodies. RESULTS: The recombinant fusion proteins showed no relevant IgE reactivity and exhibited more than 1000-fold reduced allergenic activity in basophil activation tests. On immunization of mice and rabbits, the fusion proteins induced Fel d 1-specific IgG antibodies that inhibited the binding of allergic patients' IgE to the allergen without allergic sensitization to Fel d 1. CONCLUSION: The described recombinant fusion proteins exhibit strongly reduced IgE-mediated allergenic activity, contain less than 40% of the Fel d 1 sequence, and thus lack many of the specific T-cell epitopes. Therefore they should represent safe vaccines for the treatment of cat allergy.
BACKGROUND: Allergen-specific immunotherapy is clinically effective for the treatment of cat allergy but shows a high rate of side effects. OBJECTIVE: We sought to engineer recombinant fusion proteins for cat immunotherapy that allow reducing both IgE-mediated and T cell-mediated side effects. METHODS: Fusion proteins consisting of the hepatitis B virus-derived PreS domain and 2 nonallergenic Fel d 1-derived peptides were expressed in Escherichia coli and purified. IgE reactivity and allergenic activity of Fel d 1 and the fusion proteins were compared by using IgE-binding assays and basophil activation tests in patients with cat allergy. Mice and rabbits were immunized subcutaneously with Fel d 1 and the fusion proteins to investigate the allergenicity of the vaccines and the development of Fel d 1-specific IgG antibodies. RESULTS: The recombinant fusion proteins showed no relevant IgE reactivity and exhibited more than 1000-fold reduced allergenic activity in basophil activation tests. On immunization of mice and rabbits, the fusion proteins induced Fel d 1-specific IgG antibodies that inhibited the binding of allergic patients' IgE to the allergen without allergic sensitization to Fel d 1. CONCLUSION: The described recombinant fusion proteins exhibit strongly reduced IgE-mediated allergenic activity, contain less than 40% of the Fel d 1 sequence, and thus lack many of the specific T-cell epitopes. Therefore they should represent safe vaccines for the treatment of cat allergy.
Authors: S R Durham; S M Walker; E M Varga; M R Jacobson; F O'Brien; W Noble; S J Till; Q A Hamid; K T Nouri-Aria Journal: N Engl J Med Date: 1999-08-12 Impact factor: 91.245
Authors: Hans Grönlund; Tomas Bergman; Kristofer Sandström; Gunvor Alvelius; Renate Reininger; Petra Verdino; Alexander Hauswirth; Karin Liderot; Peter Valent; Susanne Spitzauer; Walter Keller; Rudolf Valenta; Marianne van Hage-Hamsten Journal: J Biol Chem Date: 2003-05-05 Impact factor: 5.157
Authors: Nicole Schmitz; Klaus Dietmeier; Monika Bauer; Melanie Maudrich; Stefan Utzinger; Simone Muntwiler; Philippe Saudan; Martin F Bachmann Journal: J Exp Med Date: 2009-08-10 Impact factor: 14.307
Authors: Katharina Marth; Isabella Breyer; Margarete Focke-Tejkl; Katharina Blatt; Mohamed H Shamji; Janice Layhadi; Anna Gieras; Ines Swoboda; Domen Zafred; Walter Keller; Peter Valent; Stephen R Durham; Rudolf Valenta Journal: J Immunol Date: 2013-02-25 Impact factor: 5.422
Authors: Inna Tulaeva; Carolin Cornelius; Petra Zieglmayer; René Zieglmayer; René Schmutz; Patrick Lemell; Milena Weber; Margarete Focke-Tejkl; Alexander Karaulov; Rainer Henning; Rudolf Valenta Journal: EBioMedicine Date: 2020-08-24 Impact factor: 8.143